Previous close | 27.78 |
Open | 27.82 |
Bid | 27.75 x 3200 |
Ask | 27.76 x 3000 |
Day's range | 27.72 - 28.12 |
52-week range | 25.61 - 42.22 |
Volume | |
Avg. volume | 43,832,203 |
Market cap | 157.135B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 75.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (6.05%) |
Ex-dividend date | 25 Jan 2024 |
1y target est | N/A |
NEW YORK, March 20, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2024 Performance Report, to be issued that morning.
NEW YORK, March 13, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
NEW YORK, March 12, 2024--Adcetris Ph3 TLR